FDA Approves First New Schizophrenia Drug in Decades

An FDA official said the latest approval will offer a new alternative to existing antipsychotic medications for schizophrenia patients.

The U.S. Food and Drug Administration (FDA) in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new treatment for adults with schizophrenia in over three decades.

The xanomeline and trospium chloride capsules for oral use will be marketed under the brand name Cobenfy.